AKT1 and ovarian carcinoma: The PI3K/Akt/mTOR axis is essential in abnormally proliferated ovarian cancer cells, and using pathway inhibitors to reduce pathway activity is expected to improve therapeutic effects in patients with ovarian cancer [14].